Currently, Hadassah is enrolling patients in clinical trials of the latest drugs designed to treat stomach cancer, bile duct cancer, and liver cancer.
The trials use combinations of Kitruda, Opdivo, and Atezolizumab immunotherapy drugs.
The medical center also often conducts clinical trials of drugs for lymphoma, metastatic melanoma, lung cancer, kidney cancer, and breast cancer with metastases.
iMER (International Medical Evaluation and Referrals)
iMER is a Worldwide Health Services Provider and the exclusive representative of Hadassah University Hospital in Greece and Cyprus since March 2007.
To verify the possibility of participating in clinical trials and to obtain detailed enrollment information, please contact our staff.
Safety and control
Clinical trials usually have global nature and take place simultaneously in the USA, Europe, and Israel. In Israel, they are closely monitored and supervised by the Helsinki Committee (the Helsinki Declaration, developed by the World Medical Association, a set of ethical principles for the medical community regarding research ethics and human experiments).
Hadassah doctors constantly provide reports to this committee and to a parent company located outside of Israel. The patient is under very strict supervision, meets with an oncologist at each visit to the clinic, undergoes tests and examinations. All analyses are sent abroad, since all results are verified by the Helsinki Committee in Israel and abroad.
Stages of clinical trials
Clinical trials are divided into two main stages. At the earliest stage, called the “first phase”, scientists test the effects of their developed medicine on humans. The optimal dose of the drug is established and patients with oncological problems with no good prognosis by the use of conservative treatments are invited.
At the second stage, new drugs are tested, no matter whether they are chemical, biological, or immunotherapy-related, comparing their effects with the current standard. They check the effectiveness of one medicine in comparison with another or use both drugs together if one medicine is to be supplemented with another. In such a clinical study, a drug whose dose has already been established is tested, since its side effects are already known, as well as its effectiveness in the treatment of a specific cancer. Now, the place this drug will occupy in the arsenal of oncologists has to be determined: that is whether it will be primary or secondary, or a third-rate means. Or this drug can become an element of an existing treatment approved for use in a particular cancer.
To prove that the medicine the doctors want to offer the patient is really better than the existing analogs, half of the participating patients receive the old, standard treatment, and the second group receives a new drug.
Relevant clinical trials
Today, Hadassah conducts clinical trials in the field of gastric cancer. Doctors check the combination of immunotherapy (Kitruda or Opdivo) with chemotherapy. The trial studies this combination at several stages: when the disease is detected in the stomach before the operation, at the preoperative stage - a combination of immunotherapy and chemotherapy in comparison with chemotherapy alone, or when the patient already has metastases. In this case, the combination of drugs with a biological drug is checked, if there is an appropriate biological treatment for patients with metastases.
Simultaneously, clinical trials are conducted in the field of liver cancer. The already accepted medical biological treatment for liver cancer in combination with immunotherapy is being analyzed. This treatment applies to patients diagnosed with primary liver cancer without metastases after excised or ablated tumor. Oncologists strive to improve results - to eliminate or reduce the risk of a relapse.
At the same time, a clinical trial in the field of bile duct cancer has started. It involves patients with an inoperable tumor. Oncologists test the use of chemotherapy with immunotherapy in order to reduce the tumor and, possibly, even turn it into an operable and radiation-exposable. In the case of metastases, the goal of doctors is to extend the patient's life.
To learn more about participation in these trials, contact our staff.
Participation in clinical trials
Each specific clinical trial has its certain conditions. After several months, the studies are completed and new ones start, hence, the enrollment conditions change too. At the moment, the conditions are as follows:
•The patient must be in good physical condition, with functioning kidneys, healthy or normal liver function.
•This must be a patient not yet treated.
•The patient must move independently to be able to come to the hospital and return home, as sessions take place every 3 weeks.
One of dozens of successes
Four years ago, the famous Israeli oncologist, head of the Center for gastrointestinal cancer, Professor Ayala Hubert was visited by a patient with metastatic gastric cancer. According to the forecast, metastases would have spread with misfortune results. After a chemotherapy cycle that did not bring any results, the patient joined a clinical trial and received treatment with Kitruda. Within two months, the disease disappeared. After that, he continued treatment with Kitruda for another two years. There was no relapse for two years of successful treatment. Two years ago, in December, treatment was discontinued, however, the patient continues his follow-ups. In total, 4 years have passed since the beginning of the treatment. Perhaps, the Hadassah doctors completely cured a patient who, according to all forecasts, should not have recovered, since the disease was incurable. This happened only thanks to clinical trials.
If you want to take part in or learn about a nearest clinical trial, please write or call our staff.